Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Acrux Limited ( (AU:ACR) ) has shared an update.
Acrux Limited has released information regarding the top 20 option holders and distribution schedule for its new class of quoted securities, following its Appendix 2A Application for Quotation of Securities. This announcement outlines the terms and conditions as per the Options Prospectus dated 17 January 2025. The release signifies Acrux’s ongoing efforts to enhance its financial operations and market presence, which may impact its industry positioning and offer potential opportunities for stakeholders.
More about Acrux Limited
Acrux Limited is a pharmaceutical company specializing in developing and commercializing topical pharmaceuticals. With over 25 years of experience, Acrux has successfully launched several topically applied pharmaceutical products in the US and Europe. The company focuses on developing generic products for the US market, leveraging its in-house laboratories, GMP manufacturing suite, and commercial expertise to offer affordable healthcare solutions. Acrux is open to collaboration and is well-positioned for partnerships and product development.
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $8.24M
For a thorough assessment of ACR stock, go to TipRanks’ Stock Analysis page.
